Microcurrent Stimulation Therapy for Intermediate to Advanced Nonexudative Age-related Macular Degeneration
i-Lumen Scientific AUS PTY LTD · with i-Lumen Scientific, Inc. · NCT06662162
Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.
Key facts
- Compensation
- Not posted. Ask the study team before screening.
- Who can join
- Ages 60+ · All sexes
- Healthy volunteers
- Not accepted (a condition is required)
- Study type
- Interventional · Not applicable
- Target enrollment
- 100
- US sites recruiting
- 6
- Study start
- May 7, 2025
- Record last updated
- August 26, 2026
Status re-checked against ClinicalTrials.gov within the last 12 hours.
What the study is about
The goal of this clinical trial is to characterize the safety and effectiveness of the i-Lumen AMD transpalpebral microcurrent device and therapy in patients with intermediate to advanced nonexudative AMD.
Participants will
- Undergo an initial loading regimen, followed by 7 maintenance over the course of 11 months.
- Participants will return monthly through Month 14 (3 months post-last treatment) for evaluation and monitoring.
Being studied: i-Lumen AMD
Conditions: Age-Related Macular Degeneration; Age-related Macular Degeneration (ARMD); Intermediate AMD; Geographic Atrophy Secondary to Age-related Macular Degeneration
Eligibility criteria
Copied from the official record. The study team makes the final decision at screening.
Show full criteria
Key Inclusion Criteria
- Presence of at least one large druse >125 microns in diameter due to AMD.
- BCVA letter score of 35 to 70 letters (inclusive) (Snellen equivalent 6/12 to 6/60 [20/40 to 20/200])
Key Exclusion Criteria
- Any implanted electrical device(s) including deep brain stimulator, hearing or visual implants (i.e., cochlear implant, auditory brainstem implant, retinal prostheses), and/or cardiac defibrillator/pacemaker.
- Implanted metallic device within 20 cm of the Treatment electrode (study eye(s)) and/or the grounding electrode (base of the hairline on the back of the neck).
- Uncontrolled diabetes, defined as glycated haemoglobin (HbA1c) >10% (13.3 mmol/L).
- Current tobacco or tobacco-related product use or history within the past 5 years of heavy smoking (defined as, on average, more than half a pack of cigarettes per day).
- Known severe allergy to fluorescein dye.
- Medical diagnosis of severe dry eye defined as requiring either artificial tears more than six (6) times a day or prescription drops (i.e., Restasis, Xiidra, or Cequa).
- History of seizure disorders, chronic migraines and/or cluster headaches.
- History and/or evidence of diabetic retinopathy in either eye as assessed by CF, fundus fluorescein angiography (FA), and OCT, to be confirmed by the Central Reading Centre.
- Other conditions which pre-dispose to chorioretinal atrophy such as inherited retinal dystrophy (i.e., Stargardt's disease, Best's disease, pattern dystrophy, central areolar choroidal dystrophy, etc.).
- History and/or evidence of exudative AMD in the study eye as assessed by CF, FA (or OCT-A ), and OCT, to be confirmed by Central Reading Centre.
- GA involving the foveal centre, as assessed by the Central Reading Centre using AF and OCT.
- History of intravitreal injections for GA (e.g., Syfovre or Izervay).
- Treatment with photobiomodulation (PBM) therapy or short pulse laser within 12 months prior to screening.
- Glaucoma requiring ≥3 medications and/or drops per day, or history of trabeculectomy.
- History of any kind of intraocular surgery, excluding cataract surgery performed ≥3 months from Screening.
- History of yttrium aluminium garnet (YAG) laser posterior capsulotomy \<1 month from Screening.
- Visually significant cataracts and/or visually significant posterior capsular opacification.
- History of amblyopia.
Recruiting US locations
Retina Consultants San Diego
Poway, CA 92064
Site contact: Research Coordinator · 858-451-1911 · dcarbajal@rcsd.com
Retina Consultants PC
Manchester, CT 06042
Site contact: Chris Research Coordinator · 860-646-7704 x113 · cdwy@retinact.com
University Retina & Macula Associates
Lemont, IL 60439
Site contact: Clinical Research Manager · 708-765-4110 · swheatley@uretina.com
Retina Associates of Cleveland
Beachwood, OH 44122
Site contact: Diane Research Coordinator · (216) 831-5700 · dweiss@retina-assoc.com
Texas Retina Associates
Fort Worth, TX 76104
Site contact: Lori Research Coordinator · 817-334-0882 x411 · lmullen@texasretina.com
Tyler Retina Research Insitute
Tyler, TX 75703
Site contact: Melissa Long Research Coordinator · 903-597-4644 · mlong@tylerretina.com
Study contacts (from the official record)
- Meredith Mundy · 408-440-7049 · mmundy@i-lumen.com